Amgen (AMGN) Float Percentage Of Total Shares Outstanding : 99.89% (As of Apr. 30, 2024)

View and export this data going back to 1983. Start your Free Trial

What is Amgen Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Amgen's float shares is 535.76 Mil. Amgen's total shares outstanding is 536.38 Mil. Amgen's float percentage of total shares outstanding is 99.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Amgen's Insider Ownership is 0.63%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Amgen's Institutional Ownership is 49.89%.

Amgen Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Amgen's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	535.76	/	536.38
	=	99.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen (AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (NAS:AMGN) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Executives

Nancy A. Grygiel	officer: SVP & CCO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Jonathan P Graham	officer: SVP, Gen. Counsel & Secy.	2099 PENNSYLVANIA AVENUE, NW, 12TH FLOOR, WASHINGTON DC 20006
Matthew C. Busch	officer: VP, Finance & CAO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Murdo Gordon	officer: EVP Global Commercial Ops	C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154
Rachna Khosla	officer: SVP, Business Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
R Sanders Williams	director	DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Robert Eckert	director	MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245
Michael V Drake	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Derek Miller	officer: SVP, Human Resources	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Ronald D Sugar	director	10877 WILSHIRE BLVD., SUITE 1650, LOS ANGELES CA 900274
Linda H. Louie	officer: VP, Finance & CAO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Amy E Miles	director
David Piacquad	officer: SVP, Business Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Peter H. Griffith	officer: EVP & CFO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320